Original Research Article

Comparison of Friedewald’s formula, modified Friedewald’s formula and Anandaraja’s formula with direct homogenous serum LDL cholesterol method in CHD patients

Brindha Devi P.1, Ilanchezhian T.2*, Sarguru D.3, Ayyappan S.4, Karnaboopathy R.5, Aarti Karnik2, Saddam Hussain A.6

1Student in Biochemistry, Marudu Pandiyar College, Thanjavur, Tamil Nadu, India
2Department of Biochemistry, ACPM Medical College, Dhule, Maharashtra, India
3Department of Biochemistry, Dr. Vithal Rao Vikhe Patil Foundation’s Medical College, Ahmednagar, Maharashtra, India
4Statistician in Community Medicine, Shri Sathya Sai Medical College, Ammapettai, Chennai, Tamil Nadu, India
5Student, Shri Sathya Sai Medical College, Ammapettai, Chennai, Tamil Nadu, India
6Student, Shri Sathya Sai Medical College, Ammapettai, Chennai, Tamil Nadu, India

Received: 29 May 2020
Accepted: 30 June 2020

*Correspondence:
Ilanchezian T.,
E-mail: ilanbiochemistry@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Elevated serum Low-Density Lipoprotein Cholesterol (LDL-C) concentration is a well-known atherogenic risk factor with a high predictive value for coronary heart disease. An important aspect of the assessment of coronary heart disease risk for a dyslipidemic subject is the estimation of serum Low-Density Lipoprotein Cholesterol (LDL-C). There are many homogenous assays currently available for the estimation of serum LDL-C. Most clinical laboratories determine LDL-C (mg/dl) by Friedewald’s formula (FF), LD=TC-HDL-C-(TG/5). Modified Friedewald’s formula (MFF), LDL-C=(TC)-(HDL-C)-(TG/6), Recently Anandaraja and colleagues have derived a new formula for calculating LDL-C, AR-LDL-C=0.9 TC-(0.9 TG/5)-28.

Methods: It is cross-sectional study. Lipid profile data was collected from known of CHD patients, who had come for lipid profile investigation to the Central Biochemistry laboratory of ACPM Medical College and hospital. LDL-C estimation was done by direct homogenous assay and also calculated using the Friedewald’s Formula, Modified Friedewald’s Formula and Anandaraja’s Formula for assessing and validity of the LDL cholesterol.

Results: From the present study, The LDL-FF, MFW and AR are increased with levels of TGL > 200 mg/dl and decreased level of TC < 200 mg/dl seem to interfere with the estimation of Direct LDL cholesterol

Conclusions: Authors conclude that, LDL-C by direct method is most reliable and sensitive in CHD patients compare with FF, MFW, and ARF.

Keywords: Anandaraja formula, Coronary heart disease, Friedewald’s formula, Low density lipoprotein, Modified Friedewald’s formula

INTRODUCTION

The concentration of low-density lipoprotein cholesterol (LDL-C) is one of the strongest markers of atherosclerosis and predictor for assessing coronary heart disease (CHD) risk. Strong positive association between increased LDL-C and CHD has been well documented. The National Cholesterol Education Programme’s...
(NCEP) Adult Treatment Panel III (ATP III) deemed that LDL-C concentration was the primary basis for treatment and appropriate patients’ classification in risk categories. Homogenous assays for direct LDL cholesterol (D-LDL-C) estimation were developed in 1998. The Cholesterol Reference Method Laboratory Network of the Centers for Disease Control and Prevention has approved the use of five commercially available homogenous assays for LDL-C estimation.

In routine practice, most clinical laboratories estimate LDL-C concentrations in serum by Friedewald formula from the concentrations of Total Cholesterol (TC), Triglyceride (TG), and High- Density Lipoprotein Cholesterol (HDL-C).

Calculated low-density lipoprotein cholesterol estimation

Apart from above method, LDL cholesterol was calculated by following formulae: Friedewald: Friedewald low-density lipoprotein cholesterol (F-LDL-C)=TC–(TG/5+HDL-C).

Modified Friedewald: Modified Friedewald’s low-density lipoprotein cholesterol (MF-LDL-C)=TC–(TG/6+HDL-C).

Anandaraja: Anandaraja low-density lipoprotein cholesterol (A-LDL-C)=(0.9×TC)–(0.9×TG/5)–2.8.

The LDL-C calculated using Friedewald’s formula correlates well with LDL-C measured by beta quantification, but doesn’t come without any limitations.

The Friedewald’s formula cannot be used for LDL-C calculation when the subject is not fasting, when serum TG >400 mg/dl or < 100 mg/dl.

The accuracy and targets to be achieved regarding the analytical performance of LDL cholesterol were issued by National Cholesterol Education Program (NCEP) panel. As per NCEP guidelines, precision should be <4%, bias < 4% and total analytical error should be < 12%.

Limited study results from India have reached discordant conclusions on this topic. So this present study was examined correlations and concentration differences obtained by the different calculation methods with the direct method.

METHODS

Lipid profile reports was collected from known CHD patients, who had come for lipid profile investigation to the Central Biochemistry laboratory of ACPM Medical College and Hospital, Dhule. LDL-C estimation was done by direct homogenous assay and also calculated using the Friedewald’s Formula, Modified Friedewald’s Formula and Anandaraja’s Formula for assessing and validity of the LDL cholesterol.

Total cholesterol (TC) and TG levels were measured enzymatically by CHOD-PAP and GPO-PAP methods (Roche Diagnostics GmbH, Mannheim, Germany), respectively according to the manufacturer’s specifications. High-density lipoprotein cholesterol (HDL-C) was measured using a homogeneous assay without precipitation (Roche Diagnostics GmbH, Mannheim, Germany).

A homogenous enzymatic colorimetric assay offered by Kyowa Medex and distributed by Roche Diagnostics, was used to measure LDL directly.

RESULTS

From the present study, The LDL-FF, MFW and AR are increased with levels of TGL > 200 mg/dl and decreased level of TC <200 mg/dl seem to interfere with the estimation of Direct LDL cholesterol (Table 1).

DISCUSSION

Strategies for treatment of lipid abnormalities are primarily based on LDL-C concentration. Therefore, LDL-C must be accurately determined to establish a personal CHD risk profile in order to initiate dietary adjustments, drug therapy and to monitor their effects.

Anandaraja and colleagues described a new formula for LDL-C calculation in an Indian population of 1000 patients by applying multiple linear regression analysis and validated its accuracy in 1008 patients. In their study the mean LDL-C concentrations measured by a precipitation method and by their formula were 3.04±1.04 mmol/L and 2.96±0.96 mmol/L, respectively. The mean absolute difference between both methods was 0.1±0.24 mmol/L and good correlation was found (r = 0.97).

In addition, they confirmed a reduction in the false overestimation of LDL-C compared with Friedewald’s formula. Anandaraja and colleagues called for the reliability of their formula to be tested in other populations. In the past few decades attempts have been made to derive more accurate formulas for LDL-C calculation than the widely used Friedewald’s formula on the other hand, Friedewald’s formula has been shown to be relatively reliable and recommended by the NCEP as a routine method for estimation of LDL-C despite it having several well-established constraints.

It cannot be applied to samples containing TG levels >4.52 mmol/l (400 mg/dl), to non-fasting samples and to samples of patients with dysbetalipoproteinemia (Fredrickson Type III).

Although the newer formulas offered few advantages over the Friedewald’s, they have performed only marginally better, possibly due to diversity in terms of study populations and/or pathologies.

The use of only two variables- TG and TC in this formula is more likely to reduce analytical errors that are expected.
when Friedewald’s Formula is used. However, the study by Gupta et al., reported underestimation of LDL by FF at all levels of TG (ranging from 45 to 635 mg/dl).18 Demonstrating that both accuracy and precision of LDL-C analysis are critically important. Low-density lipoprotein (LDL)-cholesterol, as estimated by the Friedewald formula (FF) in routine patient care, is a central focus of clinical practice guidelines throughout the world. LDL can be calculated by FF (total cholesterol (TC) minus high-density lipoprotein (HDL)-cholesterol minus triglycerides (TGs))/5 in mg/dl) or measured directly in the laboratory.

Table 1: The significance in the result and also it the mean and standard deviation of direct LDL versus Friedewald, modified Friedewald and Anandaraja formula in TGL levels in different ranges on CHD patients.

| TGL level < 100 mg/dl | No. of Patients | Mean | Std. Deviation | Significance |
|-----------------------|-----------------|------|----------------|--------------|
| D - LDL               | 40              | 70.2500 | 6.99359       |              |
| FW - LDL              | 40              | 68.9750 | 6.71961       |              |
| MFW - LDL             | 40              | 71.3250 | 7.10142       |              |
| AR - LDL              | 40              | 65.6250 | 9.93230       |              |
| Total                 | 160             | 69.0438 | 8.01598       |              |

| TGL level - 101 - 200 mg/dl | No. of Patients | Mean | Std. Deviation | Significance |
|-----------------------------|-----------------|------|----------------|--------------|
| D - LDL                     | 40              | 93.3500 | 11.66751      |              |
| FW - LDL                    | 40              | 90.4250 | 11.24981      |              |
| MFW - LDL                   | 40              | 95.3250 | 11.67155      | 0.003        |
| AR - LDL                    | 40              | 100.4000 | 13.21576     |              |
| Total                       | 160             | 94.8750 | 12.40904      |              |

| TGL values - 201 - 300 mg/dl | No. of Patients | Mean | Std. Deviation | Significance |
|------------------------------|-----------------|------|----------------|--------------|
| D - LDL                      | 40              | 127.3500 | 18.97306      | 0.000        |
| FW - LDL                     | 40              | 121.7750 | 18.21452      |              |
| MFW - LDL                    | 40              | 130.1250 | 19.15683      |              |
| AR - LDL                     | 40              | 144.1250 | 21.41074      |              |
| Total                        | 160             | 130.8438 | 20.98563      |              |

| TGL values - 301 -400 mg/dl  | No. of Patients | Mean | Std. Deviation | Significance |
|------------------------------|-----------------|------|----------------|--------------|
| D - LDL                      | 40              | 169.1750 | 9.99202       |              |
| FW - LDL                     | 40              | 146.1250 | 8.76820       |              |
| MFW - LDL                    | 40              | 157.9250 | 9.44726       | 0.000        |
| AR - LDL                     | 40              | 183.4500 | 12.24106      |              |
| Total                        | 160             | 164.1688 | 17.13293      |              |

| TGL values - Above 400 mg/dl | No. of Patients | Mean | Std. Deviation | Significance |
|------------------------------|-----------------|------|----------------|--------------|
| D - LDL                      | 40              | 188.3250 | 14.79499      |              |
| FW - LDL                     | 40              | 159.4750 | 5.56540       | 0.000        |
| MFW - LDL                    | 40              | 173.6500 | 5.87716       |              |
| AR - LDL                     | 40              | 209.7500 | 7.91218       |              |
| Total                        | 160             | 182.8000 | 20.81932      |              |

The FF is not valid for patients with TGs >400 and in patients for type 3 dyslipoproteinemia. A number of studies have studied the impact of TG on the FF. A study by Sahu et al, noted that the mean LDL calculated by FF was significantly higher than the direct LDL measurement at TG between 1 and 300 mg/dl. Recently, a new formula for calculation of LDL-C has been proposed by Anandaraja et al. The calculation of LDL-C proposed by Anandaraja et al, (AR-LDL-C) is AR-LDL-C = 0.9 TC- (0.9 TG/5)-28. LDL was measured using direct homogenous assay (Daiichi Pure Chemicals Co. Ltd, Tokyo, Japan) in both the above studies.
Anandaraja et al, noted that FF overestimated LDL in subjects with TG <350 mg/dl (LDL was measured using heparin precipitation method in their study).19

In this study, there is not much significant difference in >100 mg/dl and 101 to 200 mg/dl. And also authors got more significant differences in above 200mg/dl of triglyceride values.

CONCLUSION

Authors conclude that, the LDL-C by direct method is most reliable and sensitive in CHD patients compare with FF, MFW, and ARF.

ACKNOWLEDGEMENTS

The author would like to acknowledge Mr. Veerabathiran (Senior Lab technician, Ezhil, Afraid, Dhanavarshini, Vijayarathna, Aparna (Bsc - MLT Students in Sathyai Medical College, Chennai), for their constant support in this work.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
3. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis. J Am Med Assoc 2001;285:2481-5.
4. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486-97.
5. Centers for Disease Control and Prevention. Cholesterol Reference Method Laboratory Network (CRMLN) Atlanta (GA): Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/labstandards/crmln_clinical.htm. Accessed 14 October 2015.
6. Rifai N, Warnick GR. Measurement of lipids, lipoproteins, and apolipoproteins. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnosis. 4th ed.
St. Louis, Missouri: Elsevier Saunders; 2006:938-952.
7. Kapoor R, Chakraborty M, Singh N. A leap above Friedewald formula for calculation of low-density lipoprotein-cholesterol. J Lab Physicians. 2015;7:11-6.
8. Ahmadi SA, Boroumand MA, Gohari-Moghaddam K, Tajik P, Dibaj SM. The impact of low serum triglyceride on LDL-cholesterol estimation. Arch Iranian Med. 2008;11(3):318-21.
9. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurements of low-density lipoprotein cholesterol: Executive summary. National Cholesterol Education Program Working Group on Lipoprotein Measurements. Clin Chem. 1995;41:1414-20.
10. Nauck M, Graziani MS, Bruton D, Cobbaert C, Cole TG, Lefevre F, et al. Analytical and Clinical Performance of a Detergent based Homogeneous LDL-Cholesterol Assay: A Multicenter Evaluation. Clin Chem. 2000;46:506-14.
11. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486-97.
12. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol: the Lipid Research Clinics Prevalence Study. J Am Med Assoc. 1986;256:2372-7.
13. Nakanishi N, Matsuo Y, Yoneda H, Nakamura K, Suzuki K, Tatara K. Validity of the Conventional Indirect Methods Including Friedewald Method for Determining Serum Low-Density Lipoprotein Cholesterol Level: Comparison with the Direct Homogeneous Enzymatic Analysis. J Occup Health. 2002;42:130-7.
14. Bairetari ET, Tzallas C, Kalientzidou M, Tselepis AD, Siamopoulos KC, Seferiadis KI, et al. Evaluation of alternative calculation methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients. Clin Biochem. 2004;37:937-40.
15. Planella T, Cortes M, Martinez-Bru C, Gonzalez-Sastre F, Ordonez-Llanos J. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Clin Chem 1997;43:808-15.
16. Hattori Y, Suzuki M, Tsushima M, Yoshida M, Tokunaga Y, Wang Y, et al. Development of approximate formula for LDL-chol, LDL-apo and LDL - chol: LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL. Atherosclerosis. 1998:138:289-99.
17. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating Low-Density Lipoprotein Cholesterol by the Friedewald Equation Is Adequate for
Classifying Patients on the Basis of Nationally Recommended Cutpoints. Clin Chem. 1990;36:15-9.

18. Gupta S, Verma M, Singh K. Does LDL-C estimation using Anandaraja's formula give a better agreement with direct LDL-C estimation than the Friedewald's formula? Indian J Clin Biochem. 2012;27(2):127-33.

19. Anandaraja S, Narang R, Godeswar R, Laksmy R, Talwar KK. Low density lipoprotein cholesterol estimation by a new formula in Indian population. Int J Cardiol. 2005;102:117-20.

Cite this article as: Brindha DP, Ilanchezhian T, Sarguru D, Ayyappan S, Karnaboopathy R, Karnik A et al. Comparison of Friedewald’s formula, modified Friedewald’s formula and Anandaraja’s formula with direct homogenous serum LDL cholesterol method in CHD patients. Int J Res Med Sci 2020;8:2904-8.